Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials (Q58393670)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

meta-analysis

0 references

title

Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

S L Bowker

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

20 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

25-31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00125-010-1933-3

15 February 2020

exact match

0 references

cites work

The Role of PPARs in Cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-010-1933-3

Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-010-1933-3

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

12 December 2020

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

1 reference

12 December 2020

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

1 reference

12 December 2020

Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea

1 reference

12 December 2020

Observational studies of treatment effectiveness: some cautions

1 reference

12 December 2020

Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research

1 reference

12 December 2020

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

12 December 2020

Estimating treatment effects using observational data

1 reference

12 December 2020

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality

1 reference

12 December 2020

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

1 reference

12 December 2020

Insulin glargine and cancer--an unsubstantiated allegation

1 reference

12 December 2020

Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study

1 reference

12 December 2020

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

1 reference

12 December 2020

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

12 December 2020

Effects of intensive glucose lowering in type 2 diabetes

1 reference

12 December 2020

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

1 reference

12 December 2020

Diabetes mellitus and risk of breast cancer: a meta-analysis

1 reference

12 December 2020

Diabetes mellitus and risk of bladder cancer: a meta-analysis

1 reference

12 December 2020

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

1 reference

12 December 2020

Does insulin therapy promote, reduce, or have a neutral effect on cancers?

1 reference

12 December 2020

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients

1 reference

12 December 2020

Fasting serum glucose level and cancer risk in Korean men and women

1 reference

12 December 2020

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

1 reference

12 December 2020

Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus

1 reference

12 December 2020

Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study.

1 reference

12 December 2020

Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis

1 reference

12 December 2020

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

12 December 2020

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

1 reference

12 December 2020

1 reference

12 December 2020

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

1 reference

12 December 2020

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

12 December 2020

Metformin and reduced risk of cancer in diabetic patients

1 reference

12 December 2020

Insulin glargine and malignancy: an unwarranted alarm

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan

1 reference

12 December 2020

Does diabetes therapy influence the risk of cancer?

1 reference

12 December 2020

10.1007/S00125-010-1933-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20959956%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference